Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.

In the analysis which accounted for all these four prognostic factors, there was a numerical trend in favor of rIX-FP compared to rFIXFc for total ABR (RR 0.75; 95% CI 0.32, 1.75; P = 0.5095) and AjBR (RR 0.82; 95% CI 0.37, 1.82; P = 0.6178), and AsBR (RR 0.42; 95% CI 0.22, 0.82; P = 0.0107) was significantly lower in subjects treated with rIX-FP versus rFIXFc (Table 3 ).

also in 268 other papers